COL14A1 and neoplasm: Notably, tipifarnib treatment increased the number of MyoCAFs, which are often associated with tumor aggressiveness and a dismal prognosis [54, 55], whereas the control group contained more COL14A1 MatrixCAFs (Fig. 4c).